Free Research Reports on ALNY, CYTR, IQNT and UNIS Issued by the Bedford Report

NEW YORK, NY -- (Marketwire) -- 01/17/13 -- The Bedford Report has released new equity reports today. As a leading provider of free in depth reports and timely market updates, Bedford is an essential resource for hundreds of thousands of investors across the country.

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company recently announced the pricing of 8 million shares of common stock at $20.13 per share.

Find out more about Alnylam Pharmaceuticals including full access to the free equity report at: www.BedfordReport.com/ALNY

CytRx Corporation (NASDAQ: CYTR) is a biopharmaceutical research and development company specializing in oncology. Shares of the company surged nearly 8 percent on more than four-times the average daily volume Wednesday.

Find out more about CytRx including full access to the free equity report at: www.BedfordReport.com/CYTR

Neutral Tandem (NASDAQ: IQNT) shares spiked 8 percent on nearly 1.5 million shares traded Wednesday. Last month, the company reported that it has definitively settled a previously disclosed dispute with one of its largest customers relating to the termination of certain long distance traffic.

Find out more about Neutral Tandem including full access to the free equity report at: www.BedfordReport.com/IQNT

Unilife Corp. (NASDAQ: UNIS) shares surged 13 percent on nearly six-times the average daily volume Wednesday. Zacks has recently upgraded the Unilife's rating to "outperform" and currently has a price target of $2.60 on the company.

Find out more about Unilife including full access to the free equity report at: www.BedfordReport.com/UNIS

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein.

A third party, Providence Media Strategies LLC has paid Equity News Circuit four hundred and fifty dollars for the publication of this news release. Neither Equity News Circuit, nor the hiring party, has a financial relationship with any company whose stock is mentioned in this release. Neither Equity News Circuit nor the hiring party are a registered investment advisor, and nothing in this report is intended as a solicitation to buy or sell any security.